Effects of N-propargyl-1-(R)aminoindan (rasagiline) in models of motor and cognition disorders

Journal of Neural Transmission, Supplement

Volumn , Issue 52, 1998, Pages 287-300

  Speiser, Z ^a   Levy, R ^b   Cohen, S ^a  

^a TEL AVIV UNIVERSITY   (Israel)

^b TEVA PHARMACEUTICALS   (Israel)

Author keywords

[No Author keywords available]

Indexed keywords

AMPHETAMINE; HALOPERIDOL; METIROSINE; N (2 PROPYNYL) 1 INDANAMINE; RASAGILINE; RESERPINE; SELEGILINE; UNCLASSIFIED DRUG; INDAN DERIVATIVE; MONOAMINE OXIDASE INHIBITOR;

AMNESIA; ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ARTICLE; BRAIN HYPOXIA; CATALEPSY; COGNITIVE DEFECT; CONTROLLED STUDY; DOSE RESPONSE; HYPOKINESIA; INTRAPERITONEAL DRUG ADMINISTRATION; MALE; MOTOR DYSFUNCTION; MOUSE; NEUROPROTECTION; NONHUMAN; ORAL DRUG ADMINISTRATION; PASSIVE AVOIDANCE; PRIORITY JOURNAL; RAT; STEREOTYPY; SUBCUTANEOUS DRUG ADMINISTRATION; AGING; ANIMAL; ANOXIA; AVOIDANCE BEHAVIOR; CHEMICALLY INDUCED DISORDER; COGNITION; DRUG EFFECT; INSTITUTE FOR CANCER RESEARCH MOUSE; MEMORY; MOTOR ACTIVITY; PATHOPHYSIOLOGY; PHYSIOLOGY; WISTAR RAT;

AGING; ALPHA-METHYLTYROSINE; ANIMALS; ANOXIA; AVOIDANCE LEARNING; CATALEPSY; COGNITION; COGNITION DISORDERS; HALOPERIDOL; HYPOKINESIA; INDANS; MALE; MEMORY; MICE; MICE, INBRED ICR; MONOAMINE OXIDASE INHIBITORS; MOTOR ACTIVITY; RATS; RATS, WISTAR;

EID: 0031596710     PISSN: 03036995     EISSN: None     Source Type: Book Series    
DOI: 10.1007/978-3-7091-6499-0_29     Document Type: Article

References (21)

1. Engberg G, Elebring Th, Nissbrandt H (1991) Deprenyl (selegiline), a selective MAO-B inhibitor with active metabolites; effects on locomotor activity, dopaminergic neurotransmission and firing rate of nigral dopamine neurons. J Pharmacol Exp Ther 259: 841-847
2. Finberg J, Youdim MBH (1985) Modification of blood pressure and nictitating membrane response to sympathetic amines by selective monoamine oxidase inhibitors, types A and B, in the cat. Br J Pharmacol 85: 541-546
3. Finberg JPM, Tenne M, Youdim MBH (1981) Tyramine antagonistic properties of AGN-1135, an irreversible inhibitor of monoamine oxidase type B. Br J Pharmacol 73: 65-74
4. Fowler CJ, Callingham BA, Mantle TJ, Tipton KF (1980) The effect of lipophilic compounds upon the activity of rat liver mitochondrial monoamine oxidase A and B. Biochem Pharmacol 29: 1177-1183
5. Gelowitz DL, Richardson JS, Wishart ThB, Yu PH, Lai C-T (1994) Chronic L-deprenyl or L-amphetamine: equal cognitive enhancement, unequal MAO inhibition. 47: 41-45
6. Heikkila RE, Davoisin JP, Finberg J, Youdim MBH (1985) Prevention of MPTP-induced neurotoxicity by AGN-1133 and AGN-1135, selective inhibitors of monoamine oxidase-B. Eur J Pharmacol 116: 313-317
7. Herrera AJ, Machado A, Cano J (1993) Ageing and monoamine turnover in the lateral geniculate and visual cortex of the rat. Neurochem Int 22: 531-539
8. Horn AS, Snyder SH (1972) Steric requirements for catecholamine uptake by rat brain synaptosomes: studies with rigid analogs of amphetamine. J Pharmacol Exp Ther 180: 523-530
9. Izquierdo I (1992) Dopamine receptors in the caudate nucleus and memory processes. Trends Pharmacol Sci 13: 7-8
10. Kalir A, Sabbagh A, Youdim MBH (1981) Selective acetylenic "suicide" and reversible inhibitors of monoamine oxidases types A and B. Br J Pharmacol 73: 55-64
11. Lamensdorf I, Youdim MBH, Finberg JPM (1995) Increase in striatal dopamine following chronic selective inhibition of MAO A or B. Isr J Med Sci 31: 739
12. McCullough LD, Sokolowsky JD, Solomone JD (1993) A neurochemical and behavioral investigation of the involvement of nucleus accumbens dopamine in instrumental avoidance. Neurosci 52: 919-925
13. Nilsson OG, Leanza G, Björklund A (1992) Acetylcholine release in the hippocampus: regulation by monoaminergic afferents as assessed by in vivo microdialysis. Brain Res 584: 132-140
14. Riederer P, Youdim MBH (1986) Monoamine oxidase activity and monoamine metabolism in brains of parkinsonian patients treated with 1-deprenyl. J Neurochem 46: 1359-1365
15. Speiser Z, Amitzi-Sonder J, Gitter S, Cohen S (1988) Behavioral differences in the developing rat, following postnatal anoxia or postnatally-injected AF-64A, a cholinergic neurotoxin. 30: 89-94
16. Speiser Z, Reicher S, Gitter S, Cohen S (1989) Tacrine or arecoline mediates reversal of anoxia- or AF-64A-induced behavioural disorders in the developing rat. Neuropharmacol 28: 1325-1332
17. Speiser Z, Amitzi-Zonder J, Ashkenazi R, Gitter S, Cohen S (1990) Central catecholaminergic dysfunction and behavioral disorders following hypoxia in adult rats. Behav Brain Res 37: 19-27
18. Skuza G, Rogoz Z, Quack G, Danysz W (1994) Memantine, anmantadine and L-deprenyl potentiate the action of L-Dopa in monoamine-depleted rats. J Neural Transm 98: 57-67
19. Wesnes (1990) Potential of moclobemide to improve cerebral insufficiency identified using a scopolamine model of aging and dementia. Acta Psychiatr Scand [Suppl] 360: 71-72
20. Youdim MBH, Finberg JPM, Levy R, Sterling J, Lerner D, Berger-Paskin T, Yellin H (1995) R-Enantiomers of N-propargyl-aminoindan compounds. Their preparation and pharmaceutical compositions containing them. United States Patent 5,457,133
21. Zornetzer, ST (1985) Catecholamine system involvement in age related memory dysfunction. Ann NY Acad Sci 444: 242-254